Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its ...
The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...